We invite you to attend the 2023 Summit on Cancer Health Disparities (SCHD23) in Seattle, WA! This conference is one of the largest gatherings of clinicians and researchers interested in cancer health disparities. Faculty from across the country will be speaking and in attendance. Dr. David Aboulafia of Virginia Mason, Dr. Hannah Linden of Fred Hutch, and Dr. Ana Maria Lopez of Sidney Kimmel Cancer Center are the Conference Chairs, along with Associate Chairs Dr. Siddhartha Yadav of Mayo Clinic and Aparna Parikh of Massachusetts General Hospital.
SCHD23 is an accredited continuing education activity (CME activity) that will foster collaborative interdisciplinary interactions and partnerships to stimulate the development of new research and clinical practices that reduce cancer health disparities and improve outcomes of the diverse patient population. Offerings include lectures, panels, and abstract presentation sessions. Register here!
Attending SCHD23 will give you an opportunity to network with top experts and learn from their expertise, research, and experience. You don’t want to miss this dynamic meeting! Register here! Early bird registration ends on April 14, 2023. The hotel reservation deadline to receive a discounted rate is April 7. Click here to book a room. Parking is available on-site for an additional fee.
The preliminary session agenda includes the following:
• Clinical trials
• Immunotherapy and cellular therapy
• Novel therapies in cancer
• Cancer care in LMIC
• Diagnostics – Pathology & Radiology
• The evolving role of machine learning in cancer care delivery
• Addressing cancer care disparities among LGBTQ, young adults, and others
• Surgical oncology services in resource-limited settings
• APP in oncology practice
• Current oncology workforce – avoiding burnout and optimizing patient care
• Screening and early detection
• Abstract sessions
We are accepting abstracts. Please visit our Abstracts page for information and to send in your research. The top three highest-scoring abstracts submitted by residents or fellows will receive complimentary registration and two free hotel nights during the conference. A resident, fellow, or trainee must be the abstract’s first author.
If you are a fellow or early career oncologist, we invite you to apply to co-author the conference proceedings publication for SCHD23. Interested in being mentored by oncologists and writing conference summaries for publication in a peer-reviewed journal? This opportunity will provide you with experience in publishing, free admission to SCHD23, and a $500 honorarium! Read the article for information and apply by emailing your CV to [email protected].
The Binaytara Foundation is a global cancer non-profit dedicated to improving access to cancer care in the United States and abroad through education and innovative program models that break down barriers and advance best practices in hematology and oncology. Binaytara Foundation’s major projects include hematology and oncology conferences, and the establishment of a cancer hospital in Nepal. Donate here to change lives!
2022 Summit on Cancer Health Disparities ASCO award Binaytara foundation Binaytara Foundation Cancer Center Binaytara Foundation education academy breast cancer BTF cancer cancer care cancer disparities cancer research cancer treatment cancer treatment in Nepal CME community oncologists conference Conferences continuing education Dr. Binay Shah Dr. Rubina Suwal events Expert Opinion faculty faculty highlight FDA approved Featured head & neck cancer surgery in Nepal healthcare equity hematological malignancies Journal leukemia Lung cancer lymphoma multiple myeloma Nepal Nepal cancer care oncology oncology CME Opinion peer-reviewed journal SCHD upcoming conferences video news Volunteer
By Dr. Inas Abuali Massachusetts General Hospital There is a paucity of available treatment options for patients with advanced papillary renalMore
On March 4, 2023, the U.S. Food and Drug Administration approved expanded use of adjuvant abemaciclib with endocrine therapy for adult patientsMore
SEATTLE, WA – The Binaytara Foundation, a non-profit organization dedicated to improving healthcare in underserved communities, is proud to announce the 2023More
By Dr. Chepsy Philip Believers Church Medical College Hospital Care of hematological cancers in India and other low- and middle-income countriesMore
On February 9th, 2023, the U.S. Food and Drug Administration approved dostarlimab-gxly for adult patients with recurrent or advanced endometrial cancer (EC)More